Fcrn Antagonists And Methods Of Use
Patent No. EP3087095 (titled "Fcrn Antagonists And Methods Of Use") was filed by Argen X on Dec 23, 2014. The application was issued on Aug 7, 2019.
Patent Summary
An isolated FcRn-antagonist consists of a variant IgG1 Fc region or an FcRn-binding fragment thereof. The Fc domains comprise amino acids Y, T, E, K, F, and Y at EU positions 252, 254, 256, 433, 434, and 436, respectively. This variant binds to FcRn with increased affinity and reduced pH dependence relative to wild-type IgG1 Fc, effectively inhibiting IgG endosomal recycling to reduce serum levels of Fc-containing agents. The antagonist is used to treat antibody-mediated disorders, such as autoimmune diseases, hyperglobulinemia, or to prevent placental transfer of antibodies. Embodiments include compositions with afucosylated N-linked glycans, bisecting GlcNac, or half-life extenders. The disclosure also covers encoding polynucleotides, expression vectors, host cells, and pharmaceutical compositions comprising the antagonist.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP3087095
- Application Number
- EP14827372A
- Filing Date
- Dec 23, 2014
- Status
- Granted And Under Opposition
- Jul 5, 2019
- Publication Date
- Aug 7, 2019
- External Links
- Slate, Register , Google Patents